Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Biodistribution

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    62 result(s) found for: Biodistribution. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-005950-27 Sponsor Protocol Number: 202100762 Start Date*: 2023-03-29
    Sponsor Name:University Medical Center Groningen
    Full Title: Molecular Imaging of Zirconium-89-labeled Brentuximab as a Tool to Investigate brentuximab biodistribution in CD30-positive Lymphoma
    Medical condition: All patients with histologically proven CD30-positive (i.e. > 1% cells) lymphomas who will be treated with brentuximab vedotin, including: Hodgkin lymphoma, T-cell lymphoma, Cutaneous T-cell lympho...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001471-23 Sponsor Protocol Number: UZBRU_VHH2_1 Start Date*: 2019-02-06
    Sponsor Name:UZ Brussel
    Full Title: Phase I/IIa study to evaluate the safety, biodistribution, radiation dosimetry and tumor imaging potential of 68GaNOTA-Anti-MMR-VHH2, a new radiopharmaceutical for in vivo imaging of Tumour-Associa...
    Medical condition: Tumour associated macrophages found in tumour lesions of two cancer types: breast cancer or melanoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004397-96 Sponsor Protocol Number: CF20112018 Start Date*: 2019-04-09
    Sponsor Name:Merete Hædersdal
    Full Title: Impact of thermo-mechanical intervention on Protoporphyrin IX accumulation and biodistribution in normal skin following topical 5-aminolevulinic acid at high and low vehicle viscosity
    Medical condition: Healthy skin on the upper back on 3 participants in study a and 12 participants in study b.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-005462-32 Sponsor Protocol Number: PHAO08-PD BioDNase Start Date*: 2008-11-13
    Sponsor Name:CHRU de TOURS
    Full Title: Effet de la rhDNase sur la biodistribution des protéases du neutrophile dans les expectorations des patients atteints de mucoviscidose
    Medical condition: Mucoviscidose
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028141 Mucoviscidosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004260-10 Sponsor Protocol Number: 52009 Start Date*: 2017-01-06
    Sponsor Name:VU Medical Centre
    Full Title: 89Zirconium-labeled pembrolizumab as predictive imaging biomarker of response and toxicity in pembrolizumab treated patients with non-small-cell lung cancer – a feasibility study
    Medical condition: Stadium IV Non-small cell lung cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005984-29 Sponsor Protocol Number: NL76248.091.20 Start Date*: 2021-06-28
    Sponsor Name:Radboud University Medical Center
    Full Title: [89Zr]Df-IAB22M2C anti-CD8 minibody PET/CT imaging to assess the in vivo distribution of CD8+ T-cells in COVID-19 patients
    Medical condition: Proven COVID-19.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-002416-16 Sponsor Protocol Number: ALLOB-RIF1 Start Date*: 2014-08-04
    Sponsor Name:Bone Therapeutics S.A.
    Full Title: A Pilot Phase IIa, Multicentre, Open, Proof-of-concept Study on the Safety and the Efficacy of Allogeneic Osteoblastic Cells (ALLOB®) Implantation in Rescue Interbody Fusion
    Medical condition: Failed lumbar fusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000021566 10050238 Spinal fusion NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000724-10 Sponsor Protocol Number: 60978 Start Date*: 2018-07-04
    Sponsor Name:Academic Medical Center
    Full Title: Targeting esophageal cancer with HDL nanoparticles: an imaging study
    Medical condition: Primary esophageal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004031-20 Sponsor Protocol Number: 0090 Start Date*: 2017-02-20
    Sponsor Name:Aarhus University Hospital
    Full Title: Determination of radiation dose for the bile acid tracer 11C-CSar in humans
    Medical condition: Patients with cholestatic liver disease and healthy humans
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10022891 Investigations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-002800-25 Sponsor Protocol Number: N14ZTP Start Date*: 2015-02-02
    Sponsor Name:Antoni van Leeuwenhoek Hospital-Nuclear Medicine department
    Full Title: Zirconium-89 Trastuzumab tracer uptake in metastatic breast cancer: A pilot study.
    Medical condition: Patients with metastatic breast cancer, newly found on 18F-FDG PET/CT, with or without HER2/neu overexpression or amplification (n=5) of one of the biopsied lesions.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005333-36 Sponsor Protocol Number: ALLOB-DU1 Start Date*: 2013-07-30
    Sponsor Name:Bone Therapeutics S.A.
    Full Title: A pilot Phase I/IIa, multicentre, open proof-of-concept study on the efficacy and safety of allogeneic osteoblastic cells (ALLOB®) implantation in non-infected delayed-union fractures
    Medical condition: Non-infected delayed-union fractures
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10017081 Fracture delayed union PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003461-96 Sponsor Protocol Number: AGO/2017/006 Start Date*: 2017-12-21
    Sponsor Name:Ghent University Hospital
    Full Title: PSMA-PET/CT for prostate cancer
    Medical condition: prostate cancer (and metastases)
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020759-30 Sponsor Protocol Number: [11C]inhibitors Start Date*: 2010-11-03
    Sponsor Name:Medizinische Universität Wien
    Full Title: A pilot study to assess [11C]elacridar and [11C]tariquidar as two positron emission tomography radiotracers for visualization of P-glycoprotein in humans.
    Medical condition: healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001597-29 Sponsor Protocol Number: HEM2012ZrOR001 Start Date*: 2012-07-10
    Sponsor Name:VU University Medical Center
    Full Title: Tumor uptake of 89Zirconium-ofatumumab and 89Zirconium-rituximab in diffuse large B cell lymphoma patients
    Medical condition: Diffuse large B cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-023757-11 Sponsor Protocol Number: myDC/pDCinstageIIImelanoma Start Date*: 2014-11-06
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Myeloid and plasmacytoid blood dendritic cells for immunotherapy of stage III melanoma patients scheduled for radical lymph node dissection
    Medical condition: melanoma patients with regional lymph node metastases (stage III)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003616-31 Sponsor Protocol Number: 89Zirconium-ipilimumab Start Date*: 2015-12-14
    Sponsor Name:VU medical center
    Full Title: Uptake and biodistribution of 89Zirconium-labeled ipilimumab in ipilimumab treated patients with metastatic melanoma
    Medical condition: Advanced melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002867-41 Sponsor Protocol Number: OPS-C-001/D-FR-01072-001 Start Date*: 2015-12-10
    Sponsor Name:Ipsen Pharma
    Full Title: An international multi-center, open-label study to evaluate safety, tolerability, biodistribution, dosimetry and preliminary efficacy of 177Lu-OPS201 for the therapy of somatostatin receptor positi...
    Medical condition: Neuroendocrine tumors (NETs)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (GB - no longer in EU/EEA) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003511-20 Sponsor Protocol Number: 201700599 Start Date*: 2019-01-30
    Sponsor Name:HOVON Foundation
    Full Title: Molecular imaging of zirconium-89-labeled atezolizumab in high-risk diffuse large B-cell lymphoma prior to atezolizumab treatment
    Medical condition: Diffuse large B-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012820 Diffuse large B-cell lymphoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003087-43 Sponsor Protocol Number: SAFER Start Date*: 2021-01-12
    Sponsor Name:Synektik Spółka Akcyjna
    Full Title: A Phase I/II Seamless Adaptive, Open label study to assess Safety, Tolerability, Radiation Dosimetry, Biodistribution, and diagnostic ability of a Novel 18F-labelled Tracer, SYN2, for Positron Emis...
    Medical condition: phase II: suspected coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-007653-12 Sponsor Protocol Number: AC-SWE-001 Start Date*: 2009-07-15
    Sponsor Name:Actelion Pharmaceuticals Sverige AB
    Full Title: Determination of ( 11 C) miglustat uptake in bone tissue and brain using Positron Emission Tomography (PET).
    Medical condition: Gaucher`s diseases type 1 and bone manifestations (patients)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 14:52:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA